C4 Therapeutics
CCCCCCCC · Stock Price
Historical price data
Overview
C4 Therapeutics is a clinical-stage biotech company at the forefront of targeted protein degradation (TPD), a transformative therapeutic modality. Its mission is to design small-molecule degraders that offer a potentially superior approach to traditional inhibition by eliminating, not just inhibiting, disease-causing proteins. The company's strategy is built on its proprietary TORPEDO® platform, a hybrid business model combining internal oncology pipeline development with high-value strategic collaborations with pharmaceutical leaders like Roche and Biogen. Despite a challenging market valuation, C4T is progressing its lead assets, Cemsidomide and CFT8919, through clinical trials in hematologic and solid tumors.
Technology Platform
The TORPEDO® platform is an integrated discovery and development engine for targeted protein degraders, focusing on novel E3 ligase recruitment and rational degrader design to eliminate disease-causing proteins.
Pipeline
5| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Cemsidomide + Dexamethasone | Multiple Myeloma | Phase 2 | |
| Cemsidomide + Elranatamab | Multiple Myeloma (MM) | Phase 1 | |
| CFT1946 + Trametinib + Cetuximab | Solid Tumors | Phase 1 | |
| CFT8634 | Synovial Sarcoma | Phase 1 | |
| cemsidomide + Dexamethasone Oral | Multiple Myeloma | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
C4T competes with other pure-play TPD biotechs like Kymera, Arvinas, and Nurix, as well as large pharmaceutical companies with internal TPD efforts. Its differentiation is based on its TORPEDO® platform's focus on novel E3 ligases and the specific mechanistic profile of its clinical assets, such as CFT8919's allosteric approach to targeting resistant EGFR mutations.
